Skip to content
value.today

Biotheryx Inc.

Total raised
$93 M
2 rounds on record
Latest round
$92 M
May 2021
First round on record
May 2014
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Biotheryx Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2021$92 MNo. 2$50 to $250 million

Biotheryx Inc.: Raise no. 2, May 2021

Investors in this round

40 investors had bought by the notice of Jun 2, 2021: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$92 M of $100 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • David I. Stirling · Executive Officer, Director
  • Dung W.H. Thai · Executive Officer
  • Frank W.H. Mercurio · Executive Officer
  • Jaime A. Donadio · Executive Officer
  • Kyle W.H. Chan · Executive Officer
  • Robert F. Williamson · Executive Officer, Director
  • Christopher A. Devine · Director
  • Jack A. Noelke · Director
  • Louis W.H. DeGennaro · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jaime A. Donadio, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 2, 2021. Read the notice at the SEC.

equitySEC
May 2014$1 MNo. 1Under $2 million

Biotheryx Inc.: Raise no. 1, May 2014

Investors in this round

10 investors had bought by the notice of Jun 10, 2014: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Stirling, PhD · Executive Officer, Director
  • Frank Mercurio, PhD · Executive Officer
  • Kyle Chan, PhD · Executive Officer
  • Lawrence Zaslow · Executive Officer, Director
  • Louis DeGennaro, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Issuer may engage registered broker-dealer or placement agents for introduction of investors”
  • On the use of proceeds: “A portion of the offering proceeds will be used for working capital and may include salaries”

Signed by Lawrence Zaslow, President. Source: SEC Form D, newest notice filed Jun 10, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Biotheryx Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2021).

    SEC Form D · Jun 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2021

That is all the official record says: Biotheryx Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Biotheryx Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 40 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biotheryx Inc.
NameRoleNamed in
David I. StirlingExecutive officerJun 2021
Dung W.H. ThaiExecutive officerJun 2021
Frank W.H. MercurioExecutive officerJun 2021
Jaime A. DonadioExecutive officerJun 2021
Kyle W.H. ChanExecutive officerJun 2021
Robert F. WilliamsonExecutive officerJun 2021
David Stirling, PhDExecutive officerJun 2014
Frank Mercurio, PhDExecutive officerJun 2014
Kyle Chan, PhDExecutive officerJun 2014
Lawrence ZaslowExecutive officerJun 2014
Christopher A. DevineDirectorJun 2021
David I. StirlingDirectorJun 2021
Jack A. NoelkeDirectorJun 2021
Louis W.H. DeGennaroDirectorJun 2021
Robert F. WilliamsonDirectorJun 2021
David Stirling, PhDDirectorJun 2014
Lawrence ZaslowDirectorJun 2014
Louis DeGennaro, PhDDirectorJun 2014